Acumen Pharmaceuticals (NASDAQ:ABOS – Get Rating) and Coeptis Therapeutics (NASDAQ:COEP – Get Rating) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, valuation, dividends, profitability, analyst recommendations, institutional ownership and risk. Risk & Volatility Acumen Pharmaceuticals has a beta of […]
Acumen Pharmaceuticals (NASDAQ:ABOS – Get Rating) and Repligen (NASDAQ:RGEN – Get Rating) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, risk, profitability, valuation, earnings and dividends. Risk and Volatility Acumen Pharmaceuticals has a beta of -1.55, suggesting […]
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS – Get Rating) saw a large decline in short interest in the month of May. As of May 15th, there was short interest totalling 159,800 shares, a decline of 26.3% from the April 30th total of 216,800 shares. Currently, 0.6% of the shares of the company are short sold. Based on […]
Cantor Fitzgerald began coverage on shares of Acumen Pharmaceuticals (NASDAQ:ABOS – Get Rating) in a report issued on Thursday, The Fly reports. The brokerage issued an overweight rating and a $13.00 price objective on the stock. Other research analysts also recently issued research reports about the company. Credit Suisse Group lowered their target price on […]
Intrepid Financial Planning Group LLC acquired a new stake in shares of Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS – Get Rating) during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund acquired 10,000 shares of the company’s stock, valued at approximately $54,000. A number of other institutional investors also […]